Elevated Lipoprotein(a) Tracked Across the Full Carotid Atherosclerosis Pathway
A higher lipoprotein(a) burden was tied to every major step of carotid disease progression in the Suita Study, from first plaque formation to the development of hemodynamically significant stenosis. In a prospective cohort of 3,272 Japanese adults free of cardiovascular disease and carotid plaque at baseline, those with Lp(a) at or above 50 mg/dL carried a materially higher long-term vascular risk than participants with Lp(a) below 15 mg/dL.
The pattern was not confined to one stage of disease. It extended from incident plaque detection to ongoing wall thickening and, finally, to luminal narrowing of at least 50%. That sequence matters biologically because Lp(a) is not simply a passive lipid marker; it carries proatherogenic and prothrombotic properties that can plausibly influence both plaque formation and plaque evolution over time.
Plaque Appeared Earlier in Participants With Higher Lp(a)
Baseline assessment captured adults with a mean age of 58.0 years, and 57.9% were women. Follow-up carotid ultrasonography continued biennially through June 2016, giving the analysis a long view of disease accumulation rather than a snapshot. Median follow-up reached 11.5 years, long enough for subtle differences in plaque biology to become clinically visible.
Incident carotid plaque was defined as a maximal intima-media thickness of at least 1.7 mm in the carotid artery. During follow-up, 1,432 participants developed plaque. Compared with the reference group with Lp(a) below 15 mg/dL, the multivariable-adjusted hazard ratio for incident plaque was 1.27 for those with Lp(a) at or above 50 mg/dL, with a 95% confidence interval of 1.01 to 1.61.
This is a modest relative increase, but it is the kind of difference that accumulates quietly over years and then emerges as a measurable burden of disease in midlife and later life. In practical terms, higher Lp(a) appears capable of shifting the carotid artery toward earlier plaque initiation rather than merely accelerating an already established lesion.
Faster Intima-Media Thickening Followed the Same Gradient
The study did not stop at binary plaque formation. Investigators also modeled annual changes in maximal intima-media thickness using linear mixed-effects analysis, which allowed repeated imaging data to be treated as a longitudinal trajectory rather than isolated measurements.
Among participants with Lp(a) at or above 50 mg/dL, annual maximal IMT progression was faster than in those below 15 mg/dL, with a beta coefficient of 0.014 mm per year and a 95% confidence interval from 0.003 to 0.025. The difference is small in absolute terms, but atherosclerosis is rarely built in large increments. Vessel-wall remodeling across more than a decade can translate a tiny annual change into a meaningful structural shift.
Atherosclerosis often advances in silence. This cohort shows how the silent phase can be measured long before critical narrowing appears.
From Plaque to Stenosis, the Risk Rose Again
The final step in the analysis asked a sharper clinical question: once plaque had appeared, did higher Lp(a) also predict progression to more advanced obstruction? It did. Progression to ≥50% carotid stenosis was associated with high Lp(a), with a multivariable-adjusted odds ratio of 2.29 and a 95% confidence interval of 1.15 to 4.57.
This stage is especially relevant to bedside decision-making because stenosis is the point at which anatomy begins to intersect more directly with cerebrovascular risk stratification. A marker that predicts both plaque initiation and progression to stenosis is more informative than one that tracks only early lesion formation. Here, Lp(a) behaved like a marker of sustained vascular injury rather than a one-time trigger.
The biology fits the observation. Lp(a) contains an apolipoprotein(a) component that has structural homology with plasminogen, which helps explain its association with thrombosis and impaired fibrinolysis. At the same time, its cholesterol-rich cargo can contribute to arterial deposition and plaque expansion. Those dual effects create a plausible route from initial intimal change to a tighter, more advanced lesion.
Screening Relevance for Long-Term Risk Accumulation
The most actionable implication of the study is not that every elevated Lp(a) measurement demands immediate intervention, but that risk accumulates across multiple carotid endpoints in a predictable direction. Adults with Lp(a) ≥ 50 mg/dL did not merely show an association with one isolated imaging abnormality; they showed a consistent link to plaque onset, faster IMT progression, and greater odds of stenosis.
That pattern supports earlier identification of patients who may warrant closer vascular surveillance and more intensive global risk-factor management. In a population study like Suita, the signal is particularly important because participants entered the cohort without known cardiovascular disease and without carotid plaque at baseline. The finding therefore speaks to incident disease, not just worsening of pre-existing atherosclerosis.
The clinical value of Lp(a) lies in what it adds beyond standard lipid testing. Low-density lipoprotein cholesterol can be lowered aggressively, but elevated Lp(a) often remains genetically determined and relatively stable over time. When a biomarker marks both early and advanced carotid disease, it can help explain residual risk that conventional lipid panels fail to capture.
What This Cohort Can and Cannot Prove
This was an observational analysis, so causality cannot be assigned from these results alone. The cohort does not prove that lowering Lp(a) would necessarily prevent plaque formation or reverse carotid stenosis. It does show a coherent epidemiologic pattern that strengthens the case for Lp(a) as a vascular risk marker in everyday preventive cardiology.
The endpoint definitions were also specific to carotid ultrasonography, which is a strength for structural vascular follow-up but does not directly substitute for coronary imaging or hard cardiovascular events. Even so, the longitudinal design, repeated imaging, and progression analysis give the study unusual depth for understanding atherosclerotic evolution over time.
For clinicians, the message is direct: high lipoprotein(a) aligned with a full continuum of carotid injury in this Japanese population, and the association persisted from the first detectable plaque through to advanced stenosis. The study leaves an obvious next question on the table—whether targeted Lp(a)-lowering therapy can interrupt that progression before carotid narrowing becomes established.